DDR1 and colon carcinoma: They have particularly demonstrated that pharmacological inhibition of DDR1-BCR signaling axis decreased invasion and metastatic processes in colon carcinoma, suggesting that DDR1 targeting could be an efficient co-treatment strategy in colon carcinoma (28, 29).